Córdova PN, Hernández-Valencia M

Language: Spanish
References: 47
Page: 70-78
PDF size: 831.25 Kb.

ABSTRACT

Adipose tissue is not just a lipids deposit that provides energy, since also participates in the metabolic homeostasis upon secreting several bioactives proteins, found into this proteins the adiponectin, polipeptide constituted by 244 aminoacids and molecular weight of 30 kDa. This protein module numerous metabolic processes, including glucose uptake and free fatty acids catabolism, increasing insulin sensibility and at the same time with increase in β-oxidation; giving as result the reduction in free fatty acids levels and reduction in intracellular tryglicerides contained in liver and muscle. This hormone plays an important action in diverse metabolic dysfunctions, as well as in different physiological changes that accompany the human life. In newborn adiponectin concentration has been correlated with adipose cell size. However, in childhood diminish the concentrations of adiponectin and this change is due to increase in postnatal weight. Pregnancy has been associated with a decrease in adiponectin concentrations, compared with not pregnancy women. In posmenopause the mechanisms by which the hormonal therapy reduces the adiponectin levels does not know completely, but thinks that estradiol levels are the responsible. In the obesity an inverse correlation is found with adiponectin, besides this hormone acts with antiaterogenic function and have been described it antinflamatory properties. The function from hormones secreted by the adipose tissue in the physiology and the physiopathology of the endocrine impairment have taken importance, since is considered as a key piece in the development of insulin resistance, overall when has a great food intake. However, the mechanism of this adipocine to induce all the metabolic changes are described is very complex and not yet are understood in its totality.

REFERENCES

1. Kershaw E, Jeffrey S. Adipose Tissue as an Endocrine Organ. J Clin Endocrinol Metab 2004; 89: 2548-56.

2. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 6: 2442-50.

3. Bloomgarden ZT. Developments in diabetes and insulin resistance. Diabetes Care 2006; 29: 161-7.

4. Broedl U, Lehrke M, Fleisher-Brielmaier E. Genetic variants of adiponectin receptor 2 are associated with increased adiponectina levels and decreased triglyceride/VLDL levels in patients with metabolic syndrome. Card Diabetology 2006; 5: 111-7.

5. Hu E, Liang P, Spiegelman BM. AdipoQ is novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-703.

6. Scherer PE, William S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-9.

7. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and Insulin Resistance. J Endocrinol Metab 2004; 89: 44-52.

8. Constantino D. Serum leptin levels and body composition in posmenopausal women: effects of hormone therapy. Menopause 2004; 11: 466-73.

9. Kershaw E, Flier J. Adipose Tissue as an Endocrine Organ. J Endocrinol Metab 2004; 89: 2548-56.

10. Kadowaki T, Yamauchi T. Adiponectin and Adiponectin Receptors. Endocrine 2005; 26: 439-51.

11. Díez J, Iglesias P. The role of the novel adipocyte -derived hormone adiponectin in humane disease. Eur J Endocrinol 2003; 143: 293-300.

12. Kanaya M, Harris T, Goodpasteur H. Adipocytokines attenuate the association between visceral adiposity and diabetes in older adults. Diabetes Care 2004; 27: 1375-9.

13. Zárate A, Saucedo R, Basurto L, Hernández M. Síndrome Metabólico en la Menopausia. En: Delgado J, Fernández del Castillo C (eds.). Ginecol Reproduc Hum. Temas Selectos. México: Colegio Mexicano de Especialistas en Ginecología y Obstetricia; 2006, Tomo II, p. 93-100.

14. Dunger D, Ong K. Abundante of adiponectin in the newborn. Clin Endocrinol 2004; 61: 416-517.

15. Combs TP, Berg AH, Rajala MW, Klebanov S, Iyenga RP, Jimenez-Chillaron JC, et al. Sexual differentiation, pregnancy, caloric restriction, and aging affect the adipocytespecific secretory protein adiponectina. Diabetes 2003; 52: 268-76.

16. Kotani Y, Yokota I, Kitamura Seiko, Matsuda J, Naito E, Kuroda Y. Plasma adiponectina levels in newborn are higher than those in adults and positively correlated with birth weight. Clinical Endocrinol 2004; 61: 418-23.

17. Matsuda J, Yokota IM, Murakami T, Natio E, Ito M, Shima K, Kuroda Y. Dynamic chances in serum leptin concentrations during the fetal and neonatal periods. Pediatric Research 1999; 45: 71-5.

18. Soriguer EFJ, Esteva de Antonio I, Tinahones FJ, Pareja A. Adipose tissue fatty acids and size and number of fat cells from birth to 9 years age- a cross-sectional study in 96 boys. Metabolism 1996; 45: 1395-401.

19. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children and adolescent. N Engl J Med 2004; 350: 2362-74.

20. Winer JC, Zern TL, Taksali SE, Dziura J, Cali AM, Wollschlager M, et al. Adiponectin in childhood and adolescent obesity and its association with inflammatory markers and components of the metabolic syndrome. J Clin Endocrinol Metab 2006; 91: 4415-23.

21. Ong K, Frystyk J, Flyvbjerg A, Petry JC, The Avon Longitudinal Study of Parents and Children Study Team, Ness A, Dunger DB. Sex-Discordant Associations with Adiponectin Levels and Lipid Profiles in Children. Diabetes 2006; 55: 1337-41.

22. Cruz M, García-Macedo R, García-Valerio Y, Gutierrez M, Medina-Navarro R, Duran G, et al. Low adiponectin levels predict type 2 diabetes in Mexican children. Diabetes Care 2004; 27: 1451-3.

23. Galván RE, Basurto L, Saucedo R, Campos R, Hernández-Valencia M, Zárate A. Variación de adiponectina en el ciclo menstrual. Ginecol Obstet Mex 2007; 75: 435-8.

24. Iñiguez G, Soto N, Avila A, Salazar T, Ong K, Dunger D, Mericq V. Adiponectin levels in the first two years of life in prospective cohort: relations with weight gain, leptin levels and insulin sensitivity. J Clin Endocrinol Metab 2004; 89: 5500-3.

25. Kleiblová P, Springer D, Haluzik M. The influence of hormonal changes during menstrual cycle on serum adiponectin concentrations in healthy women. Physiol Res 2006; 55: 661-6.

26. Zárate A, Saucedo R. Un análisis de la ubicación clínica del síndrome metabólico. Gac Med Méx 2006; 142: 27-30.

27. Bruns CM, Kemnitz JW. Sex hormones, insulin sensitivity, and diabetes mellitus. ILAR J 2004; 45: 160-9.

28. Thyfault JP, Hedberg EM, Anchan RM, Thorne PO, Christy MI, Newton ER, et al. Gestational Diabetes Is Associated with depressed Adiponectin levels. J Soc Gynecol Investig 2005; 12: 41-6.

29. Hulver MW, Salch O, MacDonald KG, Pories WJ, Barakat HA. Ethnic differences in adiponectina levels. Metabolism 2004; 53: 1-3.

30. Winzer C, Anger O, Festa A, Schneider B, Roden M, Pacini G, Funahashi T. Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care 2004; 27: 1721-7.

31. Friedman CI, Kimm MH. Obesity and its effect on reproductive function. Clin Obstet Gynecol 1985; 28: 645-63.

32. Morán C, Hernández E, Ruiz JE, Fonseca ME, Bermúdez JA, Zarate A. Upper Body obesity and hyperinsulinemia are associated with anovulation. Gynecol Obstet Invest 1999; 47: 1-5.

33. Kissebah AH, Vydelingum N, Murray R, Evans DJ, Hartz AJ, Kalkhooff RK, Adams PW. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982; 54: 254-60.

34. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: 12- year follow-up of participants in the population study of women in Gothenburg Sweden. Br Med J 1984; 289: 1257-61.

35. Jee A, Lee JW, Lee HR, Lee DC. Plasma adiponectina levels in postmenopausal women with or without long-term hormone therapy. Maturitas 2005; 54: 65-71.

36. Mahabir S, Baer D, Johnson LL, Roth M, Campbell W, Clevidence B, et al. Body Mass Index, percent body fat, and regional body fat distribution in relation to leptin concentrations in healthy, non-smoking postmenopausal women in a feeding study. Nutr J 2007; 6: 3-10.

37. Tanko LB, Bruun JM, Alexandersen P. Novel associations between bioavailable estradiol and adipokines in elderly women with different phenotypes of obesity: implications for atherogenesis. Circulation 2004; 110: 2246-52.

38. Padrón ML, Hernández I, Cervera-Aguilar R, Ayala R. Correlación de dos fórmulas para calcular insulinoresistencia. Ginecol Obstetr Méx 2001; 69: 233-8.

39. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamato Y, et al. Plasma concentrations of a novel adipose-specific protein , adiponectin, type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-9.

40. Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J, et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003; 52: 942-7.

41. Hsueh WA, Quinones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardio 2003; 92: 10-7.

42. Sarafidis PA, Bakris GL. Insulin and Endotelin: An Interplay Contributing to Hypertension Development? J Clin Endocrinol 2007; 92: 379-85.

43. Goldstein BJ, Scalia R. Adiponectin: A novel Adipokine Linking adipocytes and vascular function. J Clin Endocrinol Metab 2004; 89: 2563-8.

44. Ouchi N, Kobayashi H, Kihara S, Kumada M, Sato K, Inoue T, et al. Adiponectin stimulates angiogenesis by promoting cross- Talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 2004; 279: 45021-6.

45. Berg H, Scherer P. Adipose tissue, Inflammation, and Cardiovascular. Disease American Heart Association 2005; 52: 41-8.

46. Scherer C. Seizures and non-ketotic hyperglycemia. Presse Med 2005; 34: 1084-6.

47. Giamila F. Tejido Adiposo, Adipocinas e Inflamación. Phf JACI 2005; 115: 911-9.